Skip to main content
. 2019 Dec 10;21(1):e8. doi: 10.4142/jvs.2020.21.e8

Table 1. Demographic data, ASA physical status, tumor location, surgical approach and pre-anesthetic therapy in dogs that underwent elective rostrotentorial or transfrontal craniectomy.

Information recorded Sevo-Op Sevo-Dex P value
No. of animals 8 13 -
Age (yr) 9.64 (± 2.56) 10.22 (± 1.85) 0.59
Sex (No.) 5F, 3M 6F, 7M 0.66
Breed (No.) 1 Crossbreed; 1 French Bulldog; 1 German Shepherd; 1 Golden Retriever; 2 Labrador Retriever; 1 Springer Spaniel; 1 Staffordshire Bull Terrier 2 Crossbreed; 1 Dobermann; 1 German Shepherd; 1 Labrador Retriever; 1 Newfoundland; 1 Poodle; 1 Springer Spaniel; 1 Stabyhoun; 1 Staffordshire Bull Terrier; 1 Weimaraner; 2 West Highland White Terrier N/A
ASA status (No.) 2 ASA-2, 6 ASA-3 3 ASA-2, 10 ASA-3 0.99
Tumor location (No.) 5 Frontal 5 Frontal 0.38
3 Olfactory 6 Olfactory
2 Olfactory + Frontal
Intra vs. extra-axial (No.) 1 Intra-axial 2 Intra-axial 0.99
7 Extra-axial 11 Extra-axial
Surgical approach (No.) 2 Rostrotentorial 2 Rostrotentorial 0.62
6 Transfrontal 11 Transfrontal
Pre-anesthetic therapy (No. [dose in mg/kg]) 7 Mannitol (0.5) 9 Mannitol (0.5) 0.61
7 Phenobarbital (2.5 [1.6–2.9]) 12 Phenobarbital (2.5 [1.5–3]) 0.99
8 Dexamethasone (0.2 [0.05–0.2]) 11 Dexamethasone (0.2 [0.2–0.4]) 0.50

Drug doses are expressed as [median (range)].

ASA, American Society of Anesthesiologists; Group Sevo-Op, sevoflurane and short acting opioid infusion; Group Sevo-Dex, sevoflurane and dexmedetomidine infusion; NA, not available.